dabigatran   Click here for help

GtoPdb Ligand ID: 6380

PDB Ligand
Compound class: Synthetic organic
Comment: Note that the Wikipedia entry refers to the prodrug.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 10
Topological polar surface area 150.22
Molecular weight 471.2
XLogP 2.73
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CCN(C(=O)c1ccc2c(c1)nc(n2C)CNc1ccc(cc1)C(=N)N)c1ccccn1
Isomeric SMILES OC(=O)CCN(C(=O)c1ccc2c(c1)nc(n2C)CNc1ccc(cc1)C(=N)N)c1ccccn1
InChI InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
InChI Key YBSJFWOBGCMAKL-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Dabigatran is a thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and may be used post-operatively (esp following orthopedic surgery). Because the antithrombotic effects of dabigatran are more predictable than those of warfarin, regular blood testing to monitor clotting level is not required. In April 2014 this drug was approved by the US FDA for the additional indications of deep venous thrombosis (DVT) and pulmonary embolism (PE).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Dabigatran etexilate is metabolized to dabigatran by a serum esterase in the plasma and liver. Dabigatran, is a synthetic, competitive and reversible inhibitor of the serine protease, thrombin. Thrombin inhibition interupts the conversion of fibrinogen to fibrin in the coagulation cascade and consequently prevents clot formation.